The CXO Sector has also surged! WUXI APPTEC's net income in the first half is expected to double, rising over 9%.

On July 11, according to Ge Longhui, today's CNI Biomedicine Index, innovative drugs, medical outsourcing, and other major medical concepts strengthened. WUXI XDC rose over 9%, and WUXI APPTEC AH Stocks rose over 9%, driving the Hang Seng Biotech Index up 1.5%. In news, WUXI APPTEC is expected to earn a pre-profit of 8.561 billion yuan in the first half of the year, a year-on-year increase of 101.92%, with a quarter-on-quarter growth of 18.54%, exceeding expectations. Despite ongoing global trade obstacles, WUXI APPTEC's orders have barely been affected, continuing to grow, once again demonstrating the irreplaceability of domestic CXOs. With the biopharmaceutical legislative process stalled and the company's fundamentals continuing to improve, the stock price has risen over 170% from last year's low. Bohai Securities points out that current global healthcare industry financing has stabilized, pharmaceutical market R&D expenditures are continuously increasing, and the ROI on new drug R&D is declining, providing ample opportunities for CXO companies and continuous expansion in the industry. The SW Medical R&D outsourcing Sector is stabilizing and showing signs of recovery in Q1 2025, with leading companies accelerating revenue and performance in Q1 2025. Notable products and their performance as of the time of publication: Hang Seng Health Care ETF (159892), a global pharmaceutical industry representative, as of publication is up 0.93%, having gained over 54% year-to-date, tracking the Hang Seng Biotech Index, with WUXI BIO as the second largest weighted stock (9.23%) and WUXI APPTEC as the tenth largest weighted stock (2.7%). The Star medical ETF funds (588130), which represent the biomedicine of the Star Board, as of publication is up 1.19%, covering fields such as innovative drugs and innovative devices, with the top ten component stocks including United Imaging Healthcare, BEIGENE, BGI Genomics, and JUNSHI BIO among other segment leaders.